• 1
    Papadopoulos DP, Papademetriou V. Resistant hypertension: diagnosis and management. J Cardiovasc Pharmacol Ther. 2006;11(2):113118.
  • 2
    Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44(4):398404.
  • 3
    Moser M, Franklin S. Hypertension management: results of a new national survey for the Hypertension Education Foundation: Harris Interactive. J Clin Hypertens (Greenwich). 2007;9(5):316323.
  • 4
    2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21(6):10111053.
  • 5
    Konstantopoulou AS, Papargyriou IK, Antoniadou ES, et al. Masked hypertension: a new entity under investigation. Hellenic J Cardiol. 2006;47(4):232235.
  • 6
    Pickering TG, Davidson K, Gerin W, et al. Masked hypertension. Hypertension. 2002;40(6):795796.
  • 7
    Pickering TG. The ninth Sir George Pickering memorial lecture: ambulatory monitoring and the definition of hypertension. J Hypertens. 1992;10:401409.
  • 8
    Aksoy I, Deinum J, Lenders JWM, et al. Does masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients? Neth J Med. 2006;64(3):7277.
  • 9
    Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354(22):23682374.
  • 10
    McKay DW, Myers MG, Bolli P, et al. Masked hypertension: a common but insidious presentation of hypertension. Can J Cardiol. 2006;22(7):617620.
  • 11
    O'Brien E, Asmar R, Beilin L, et al; European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005;23(4):697701.
  • 12
    Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):11051187.
  • 13
    Harada K, Karube Y, Saruhara H, et al. Workplace hypertension is associated with obesity and family history of hypertension. Hypertens Res. 2006;29(12):969976.
  • 14
    Light KC, Turner JR, Hinderliter AL. Job strain and ambulatory work blood pressure in healthy young men and women. Hypertension. 1992;20:214218.
  • 15
    Fiedler N, Favata E, Goldstein BD, et al. Utility of occupational blood pressure screening for the detection of potential hypertension. J Occup Med. 1988;30:943948.
  • 16
    Schnall PL, Schwartz JE, Landsbergis PA, et al. Relation between job strain, alcohol, and ambulatory blood pressure. Hypertension. 1992;19(5):488494.
  • 17
    James GD, Pickering TG, Yee LS, et al. The reproducibility of average ambulatory, home, and clinic pressures. Hypertension. 1988;11:545549.
  • 18
    Bobrie G, Genes N, Vaur L, et al. Is “isolated home” hypertension as opposed to “isolated office” hypertension a sign of greater cardiovascular risk? Arch Intern Med. 2001;161:22052211.
  • 19
    Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004;291(11):13421349.
  • 20
    Mann SJ, James GD, Wang RS, et al. Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case-control study. JAMA. 1991;265:22262228.
  • 21
    Bjorklund K, Lind L, Zethelius B, et al. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation. 2003;107:12971302.
  • 22
    Clement DL, De Buyzere ML, De Bacquer DA, et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348(24):24072415.
  • 23
    Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension. 2000;36:894900.
  • 24
    Devereux RB, Pickering TG. Relationship between the level, pattern and variability of ambulatory blood pressure and target organ damage in hypertension. J Hypertens Suppl. 1991;9(8):S34S38.
  • 25
    Parati G, Pomidossi G, Albini F, et al. Relationship of 24-hour blood pressure mean and variability to severity of target organ damage. J Hypertens. 1987;5:9398.
  • 26
    Liu JE, Roman MJ, Pini R, et al. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med. 1999;131:564572.
  • 27
    Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation. 1997;95:14641470.
  • 28
    Fagard RH, Staessen JA, Thijs L. Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy. J Hypertens. 1997;15(12, pt 2):14931502.
  • 29
    Redon J, Campos C, Narciso ML, et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension. Hypertension. 1998;31:712718.
  • 30
    Fagard RH, Staessen JA, Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. Hypertension. 1997;29:2229.
  • 31
    Eguchi K, Kario K, Shimada K. Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. Stroke. 2003;34:24712474.
  • 32
    Palatini P. Masked hypertension: how can the condition be detected? Blood Press Monit. 2004;9(6):297299.
  • 33
    Palatini P, Winnicki M, Santonastaso M, et al. Prevalence and clinical significance of isolated ambulatory hypertension in young subjects screened for stage I hypertension. Hypertension. 2004;44:170174.
  • 34
    Stergiou GS, Salgami EV, Tzamouranis DG, et al. Masked hypertension assessed by ambulatory blood pressure versus home blood pressure monitoring: is it the same phenomenon? Am J Hypertens. 2005;18(6):772778.
  • 35
    Mancia G, Sega R, Bravi C, et al. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens. 1995;13(12, pt 1):13771390.
  • 36
    Waeber B. What is behind masked hypertension? Rev Med Suisse. 2005;1(32):20892091.
  • 37
    Pickering TG. Effects of stress and behavioral interventions in hypertension: what is masked hypertension? J Clin Hypertens (Greenwich). 2003;5(2):171174, 176.
  • 38
    Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation. 2001;104(12):13851392.
  • 39
    Imai Y, Tsuji I, Nagai K, et al. Ambulatory blood pressure monitoring in evaluating the prevalence of hypertension in adults in Ohasama, a rural Japanese community. Hypertens Res. 1996;19(3):207212.
  • 40
    Marquez Contreras E, Casado Martinez JJ, Pardo Alvarez J, et al. Prevalence of white-coat hypertension and masked hypertension in the general population, through home blood pressure measurement. Aten Primaria. 2006;38(7):392398.
  • 41
    Belkic KL, Schnall PL, Landsbergis PA, et al. Hypertension at the workplace: an occult disease? The need for work site surveillance. Adv Psychosom Med. 2001;22:116138.
  • 42
    Selenta C, Hogan BE, Linden W. How often do office blood pressure measurements fail to identify true hypertension? An exploration of white-coat normotension. Arch Fam Med. 2000;9(6):533540.
  • 43
    Obara T, Ohkubo T, Kikuya M, et al; J-HOME Study Group. Prevalence of masked uncontrolled and treated white-coat hypertension defined according to the average of morning and evening home blood pressure value: from the Japan Home versus Office Measurement Evaluation Study. Blood Press Monit. 2005;10(6):311316.
  • 44
    Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18(11):14221428.
  • 45
    Longo D, Dorigatti F, Palatini P. Masked hypertension in adults. Blood Press Monit. 2005;10(6):307310.
  • 46
    Tomiyama M, Horio T, Kamide K, et al. Reverse white-coat effect as an independent risk for left ventricular concentric hypertrophy in patients with treated essential hypertension. J Hum Hypertens. 2007;21(3):212219.
  • 47
    Kato T, Horio T, Tomiyama M, et al. Reverse white-coat effect as an independent risk for microalbuminuria in treated hypertensive patients. Nephrol Dial Transplant. 2007;22(3):911916.
  • 48
    Hara A, Ohkubo T, Kikuya M, et al. Detection of carotid atherosclerosis in individuals with masked hypertension and white-coat hypertension by self-measured blood pressure at home: the Ohasama Study. J Hypertens. 2007;25(2):321327.
  • 49
    Tomiyama M, Horio T, Yoshii M, et al. Masked hypertension and target organ damage in treated hypertensive patients. Am J Hypertens. 2006;19(9):880886.
  • 50
    Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47(5):846853.
  • 51
    Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46(3):508515.
  • 52
    Agarwal R. Hypertension diagnosis and prognosis in chronic kidney disease with out-of-office blood pressure monitoring. Curr Opin Nephrol Hypertens. 2006;15(3):309313.
  • 53
    Kuriyama S, Otsuka Y, Iida R, et al. Morning blood pressure predicts hypertensive organ damage in patients with renal diseases: effect of intensive antihypertensive therapy in patients with diabetic nephropathy. Intern Med. 2005;44(12):12391246.
  • 54
    Leitao CB, Canani LH, Kramer CK, et al. Masked hypertension, urinary albumin excretion rate and echocardiographic parameters in putatively normotensive type 2 diabetes mellitus patients. Diabetes Care. 2007;30(5):12551260.
  • 55
    Eguchi K, Ishikawa J, Hoshide S, et al. Masked hypertension in diabetes mellitus: a potential risk. J Clin Hypertens (Greenwich). 2007;9(8):601607.
  • 56
    Stergiou GS, Yiannes NJ, Rarra VC, et al. White-coat hypertension and masked hypertension in children. Blood Press Monit. 2005;10(6):297300.
  • 57
    Matsuoka S, Awazu M. Masked hypertension in children and young adults. Pediatr Nephrol. 2004;19(6):651654.
  • 58
    Lurbe E, Torro I, Alvarez V, et al. Prevalence, persistence, and clinical significance of masked hypertension in youth. Hypertension. 2005;45(4):493498.
  • 59
    Stabouli S, Kotsis V, Toumanidis S, et al. White-coat and masked hypertension in children: association with target-organ damage. Pediatr Nephrol. 2005;20(8):11511155.